CA2705410A1 - 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents - Google Patents

5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents Download PDF

Info

Publication number
CA2705410A1
CA2705410A1 CA2705410A CA2705410A CA2705410A1 CA 2705410 A1 CA2705410 A1 CA 2705410A1 CA 2705410 A CA2705410 A CA 2705410A CA 2705410 A CA2705410 A CA 2705410A CA 2705410 A1 CA2705410 A1 CA 2705410A1
Authority
CA
Canada
Prior art keywords
fluoro
alkyl
group
amino
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2705410A
Other languages
French (fr)
Other versions
CA2705410C (en
Inventor
Markus Berger
Hartmut Rehwinkel
Thomas Zollner
Ekkehard May
Jorma Hassfeld
Heike Schaecke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39575536&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2705410(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2705410A1 publication Critical patent/CA2705410A1/en
Application granted granted Critical
Publication of CA2705410C publication Critical patent/CA2705410C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/58—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compounds of formula (I), processes for their production and their use as anti-inflammatory agents.

Description

5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, A
Process for Their Production and Their Use as Anti-inflammatory Agents The present invention relates to compounds of formula I, a process for their production and their use as anti-inflammatory agents.

The most common anti-inflammatory agents are still the glucocorticoids (GCs) which are small molecules having a steroidal structure that interact with the glucocorticoid receptor (GR), whether endogenous, like cortisol, or synthetic, like dexamethasone and others. However, the application of highly potent GCs, especially over long treatment periods, led to the occurrence of undesired effects. A
number of these effects, are severe and sometimes irreversible such as e.g.
diabetes, osteoporosis, skin and muscle atrophy, glaucoma (Schacke et al., Pharmacol. & Therapeutics (2002) 96(1):23-43., Miner et al., 2005 Expert Opin.
Investig. Drugs (2005) 14(12):1527-1545.)The GCs potently inhibit pro-inflammatory cytokines and chemokines at the site of administration, whereas they elicit only limited systemic effects (O'Connell, 2003 Clin. Ther. (2003) 25(Suppl. C):C42-60;
Welker et al. Int. Arch. Allergy Immunol. (1996) 109(2):110-115, 1996, Gunther et al., 1998. Skin Pharmacol. App!. Skin Physiol. (1998) 11(1):35-42). Although locally active GCs appeared to be the ideal anti-inflammatory drugs, their application is limited due to local side effects and to insufficient efficacy in severe disease states.

Therefore, there is a great medical need for new compounds that have anti-inflammatory / immunomodulatory activity similar to the marketed GCs, and are less likely to produce undesired effects.

From the prior art of DE 100 38 639 and WO 02/10143, anti-inflammatory agents of the following general formula R' RZ HO R3 A B~ Ar are known, wherein the Ar radical comprises phthalides, thiophthalides, benzoxazinones or phthalazinones. In the experiment, these compounds show dissociations of action between anti-inflammatory and undesirable metabolic actions
2 and are superior to the previously described nonsteroidal glucocorticoids or exhibit at least just as good an action.

Compounds structurally related to those described in this patent application are disclosed in WO 2005/035518.

a b OH
3 C R

R NH

R
Due to the manufacturing process these compound always do contain a group a C
wherein the bond between a and b or between b and c may be unsaturated and which thus must contain a group selected from -CH2-CH(CH3)2, a -CH=C(CH3)2 or a -CH2-C(CH3)=CH2). Compounds of such a composition are specifically disclaimed in the present application.

Despite all efforts, the selectivity of the compounds of the prior art towards the glucocorticoid receptor (GR) compared to the other steroid receptors as well as their efficacy or potency still requires improvement.

It was therefore the object of this invention to make compounds available showing improvements of at least one aspect mentioned above.
This object has been achieved by the compounds according to the claims.

This invention therefore relates to compounds of general formula I

(I) wherein R'and R2 independently of one another, mean a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-Cio)-alkyl group, an optionally substituted (Ci-Cio)-alkoxy group, a (C1-C1o)-alkylthio group, a (C1-C5)-perfluoroalkyl group, a cyano group, a nitro group, or R1 and R2 together mean a group that is selected from the groups -O-(CH2)p O-, -O-(CH2)P CH2-, -O-CH=CH-, -(CH2)p+2-, -NH-(CH2)p+1, -N(C1-C3-alkyl)-(CH2)p+1, and -NH-N=CH-, whereby p = 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring-carbon atoms, or NR6R7, whereby R6 and R7, independently of one another, mean hydrogen, C1-C5-alkyl or (CO)-(C1-C5)-alkyl, R3 means a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-Cio)-alkyl group, a (C1-C1o)-alkoxy group, a (C1-Cio)-alkylthio group, or a (Cj-C5)-perfluoroalkyl group, R4 means a hydrogen, halogen, hydroxy, (C1-C5)-alkyl, (C1-C5)alkoxy, (C1-C5)-alkylthio, (C1-C5)-perfluoroalkyl, cyano, nitro, NR6R7, COOR9, (CO)NR6R7 or a (Ci-C5-alkylene)-O-(CO)-(Ci_C5)alkyl group
4 R5 means a group selected from -(C1-Cio)alkyl, which may be optionally partially or completely halogenated, -(C2-C1o)alkenyl, -(C2-C1o)alkynyl, (C3-C7)cycloalkyl-(Ci-C8)alkyl, (C3-C7)cycloalkyl-(Ci-C8)alkyenyl, (C3-C7)cycloalkyl-(C2-C8)alkynyl, heterocyclyl-(Ci-C8)alkyl, heterocyclyl-(C1-C8)alkenyl, heterocyclyl-(C2-C8)alkynyl, R8-(Cl -C8)alkyl, R8-(C2-C8)alkenyl, R8-(C2-C8)alkynyl, -S-(C1-C10)-alkyl, -SO2-(C1-Cio)-alkyl -S-R8, -S02-R8, -CN
-Hal, -O-(Cl-C1o)-alkyl, -NR6R7 wherein R6, R7 have the meaning defined above -O-R8, -OH

with the exception of -CH(CH3)2, or -C(CH3)=CH2 R8 means an aryl group which may optionally be substituted by 1-3 hydroxy, halogen, C1-C5-alkyl, C1-C5-alkoxy, cyano, CF3, nitro, 000(C1-C5-alkyl) or C(O)OCH2-phenyl or a heteroaryl group whereby the heteroaryl group may contain 1-3 hetero atoms which may optionally be substituted by 1-3 alkyl groups, hydroxy, halogen, cyano or C1-C5-alkoxy groups.
and their salts, solvates or salts of solvates.

One aspect of the invention relates to compounds of formula I wherein Rand R2 independently of one another, mean a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-Cio)-alkyl group, an optionally substituted (Ci-C1o)-alkoxy group, a (C1-C1o)-alkylthio group, a
5 (C1-C5)-perfluoroalkyl group, a cyano group, a nitro group, or R' and R2 together mean a group that is selected from the groups -O-(CH2)p O-, -O-(CH2)p CH2-, -O-CH=CH-, -(CH2)p+2-, -NH-(CH2)p+1, -N(C1-C3-alkyl)-(CH2)p+i, and -NH-N=CH-, whereby p = 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring-carbon atoms, or NR6R7, whereby R6 and R7, independently of one another mean hydrogen, C1-C5-alkyl or (CO)-(C1-C5)-alkyl, R3 means a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-Cio)-alkyl group, a (Cl-Clo)-alkoxy group, a (Ci-Cio)-alkylthio group, or a (C1-C5)-perfluoroalkyl group, R4 means a hydrogen atom, a hydroxy group, a halogen atom, R5 means a group selected from -(C1-C10)alkyl, which may be optionally partially or completely halogenated -(C2-C10)alkenyl, -(C2-C1o)alkynyl, (C3-C7)cycloalkyl-(C1-C8)alkyl, (C3-C7)cycloalkyl-(C2-C8-)alkenyl, (C3-C7)cycloalkyl-(C2-C$_)alkynyl, heterocyclyl-(C1-C8)alkyl, heterocyclyl-(C2-C8)alkenyl, heterocyclyl-(C2-C8)alkynyl, R8-(C1-C8)alkyl, R8-(C2-C8)alkenyl,
6 R8-(C2-C5)alkynyl, -S-(C1-C1o)-alkyl, -S-R8, -S02-R8, -S02-(C1-Clo)-alkyl, -CN, -Hal, -O-(C1-C1o)-alkyl, -NR6R7 wherein R6, R7 have the meaning indicated above -O-R8, -OH
with the exception of -CH(CH3)2, or -C(CH3)=CH2 R8 means an aryl which may optionally be substituted with 1-3 alkyl, hydroxy, halogen, cyano or C1-C5-alkoxygroups or a heteroarylgroup wherein the heteroarylgroup may contain 1-3 heteroatoms which may optionally be substituted with 1-3 alkyl, hydroxy, halogen, cyano or C1-C5-alkoxygroups, n means an integer selected from 1, 2, 3, 4, 5 and their salts, solvates or salts of solvates.
Another aspect of the invention are compounds of general formula I
according to claim 1, wherein Rand R2 independently of one another, mean a hydrogen atom, a hydroxyl group, a halogen atom, an optionally substituted (C1-Cio)-alkyl group, an optionally substituted (C1-Cio)-alkoxy group, a (C1-C5)-perfluoroalkyl group, a cyano group, or NR6R7, whereby R6 and R7, independently of one another, mean hydrogen, Cl-C5-alkyl or (CO)-(C1-C5)-alkyl, R3 means a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-Cio)-alkyl group, a (C1-C1o)-alkoxy group, or a (C1-C5)-perfluoroalkyl group, R4 means hydrogen, C1-C3-alkyl, C1-C3-alkoxy, hydroxy, halogen, R5 means a group selected from -(Ci-Clo)-alkyl, which may be optionally partially or completely halogenated -(C2-Cio)-alkenyl, -(C2-Cio)-alkynyl, -(C3-C7)cycloalkyl-(C1-C8)alkyl, -(C3-C7)cycloalkyl-(C2-C8)alkenyl, -S-(CI-Clo)-alkyl, -S02-(C1-Cj0)-alkyl, -CN, -Hal, -O-(C1-C1o)-alkyl, -NR6R7 wherein R6, R7 have the meaning defined above, -OH
with
7 the exception of -CH(CH3)2, or -C(CH3)=CH2 and their salts, solvates or salts of solvates.A further aspect of the invention are compounds of general formula I
according to claim 1, wherein R1, R2 and R3 are independently of one another hydrogen, fluorine, chlorine, bromine, a cyano group, a methoxy group, a ethoxy group, a hydroxy group, R4 is hydrogen, CI-C3-alkyl, halogen, R5 is hydroxyl group, chlorine, -S-CH3, -S-CH2-CH3, -S-CH2-CH2-CH3, -O-CH3 or -O-CH2-CH3, -O-CH2-CH2-CH3, -N-(CH3)2, -N-(CH2-CH3)2 and their salts, solvates or salts of solvates.A further aspect of the invention are compounds of general formula I
according to claim 1, wherein R1, R2 and R3 are independently of one another hydrogen, fluorine, chlorine, bromine, a cyano group, a methoxy group, a ethoxy group, a hydroxyl group, R4 is hydrogen, C1-C3-alkyl, halogen, R5 is a hydroxyl group, chlorine, -S-CH3, -S-CH2-CH3, -S-CH2-CH2-CH3, -O-CH3, -O-CH2-CH3, -O-CH2-CH2-CH3 or N(CH3)2 and their salts, solvates or salts of solvates.

Still another aspect of the invention are compounds of general formula I
according to claim 1, wherein R1, R2 and R3 are independently of one another hydrogen, fluorine, chlorine, bromine, a cyano group, a methoxy group, a ethoxy group, a hydroxyl group, R4 is hydrogen, C1-C3-alkyl, halogen, R5 is a hydroxyl group, chlorine, -S-CH3, -S-CH2-CH3, -S-CH2-CH2-CH3, -O-CH3 or -O-CH2-CH3, -O-CH2-CH2-CH3 and their salts, solvates or salts of solvates.

One aspect of the invention are compounds of general formula I according to claim 1, wherein R1 and R2 are independently of one another hydrogen, fluorine, chlorine, a methoxy group, a hydroxyl group, R3 is hydrogen, fluorine, chlorine or a methoxy group, R4 is hydrogen or fluorine, R5 is a hydroxy group, a chlorine atom, -S-CH3, -S-CH2-CH3, -O-CH3, -O-CH2-CH3 or N(CH3)2 and their salts, solvates or salts of solvates.A further aspect of the invention are compounds of general formula I
according to claim 1, wherein R1 and R2 are independently of one another hydrogen, fluorine, chlorine, a methoxy group, R3 is hydrogen, fluorine, chlorine or a methoxy group, R4 is hydrogen or fluorine, R5 is a hydroxyl group, a chlorine atom, -S-CH3, -S-CH2-CH3, -O-CH3, or -O-CH2-CH3 and their salts, solvates or salts of solvates.

Another aspect of the invention are compounds according to at least one of claims 1-4 in enantiomerically pure form and their salts, solvates or salts of solvates.Another aspect of the invention are compounds according to claim 1 selected from the list consisting of
8 5-{[1-(2-Fl uo ro-4-methoxyphenyl)-3, 3, 3-trifluoro-2-hyd roxy-2-([methylsulfanyl]methyl)propyl]amino}-1 H-quinolin-2-one 5-{[2-([Ethylsulfanyl]methyl)-1-(2-fl uoro-4-methoxyphenyl)-3, 3, 3-trifluoro-2-hydroxypropyl]amino}-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-([ethylsulfanyl]methyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl) propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(ethoxymethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3, 3,3-trifluoro-2-hyd roxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)-propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-2-(chloromethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[3,3,3-trifluoro-2-hydroxy-2-([methoxymethyl)-1 -phenylpropyl]amino}-1 H-quinolin-1 -one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(diaminomethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(4-Chloro-3-fluoro-2-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl) propyl] amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(ethoxymethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-hyd roxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one and their salts, solvates or salts of solvates.
Still another aspect of the invention are enantiomerically pure compounds according to claim 1 selected from the list consisting of5-{[1-(2-Fluoro-4-methoxyphenyl)-3, 3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1 H-quinolin-2-one
9 5-{[2-([Ethylsulfanyl]methyl)-1-(2-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-([ethylsulfanyl]methyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3, 3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(ethoxymethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-3, 3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)-propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-2-(chloromethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{[3,3,3-trifluoro-2-hydroxy-2-([methoxymethyl)-1-phenylpropyl]amino}-1H-quinolin-1-one and their salts, solvates or salts of solvates.

Another aspect of the invention are enantiomerically pure compounds according to claim 1 selected from the list consisting of 5-{(1S, 2R)[1-(2-Fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1 H-quinolin-2-one 5-{(1S, 2R)[2-([Ethylsulfanyl]methyl)-1-(2-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-1 H-quinolin-2-one 5-{(IS, 2R)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1 H-quinolin-2-one 5-{(1S, 2R)[1 -(2-Chloro-3-fluoro-4-methoxyphenyl)-2- ([ethylsulfanyl]methyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2S)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hyd roxy-2-(m ethoxym ethyl) pro pyl]a m i no}-7-fl uo ro- 1 H-quinolin-2-one 5-{(1S, 2S)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(ethoxymethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2S)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2S)[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2R)[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-2-(chloromethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5 5-{(1S, 2S)[3,3,3-trifluoro-2-hydroxy-2-([methoxymethyl)-1-phenylpropyl]amino}-1 H-quinolin-1 -one 5-{[(1S, 2R)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(diaminomethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(IS, 2S)[1-(2-Chloro-3-fluoro-4-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-
10 (hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one and their salts, solvates or salts of solvates.

A further aspect of the invention are enantiomerically pure compounds according to claim 1 selected from the list consisting of 5-{(1S, 2R)[1-(2-Fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1 H-quinolin-2-one 5-{(1S, 2R)[2-([Ethylsulfanyl]methyl)-1-(2-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-1 H-quinolin-2-one 5-{(1S, 2R)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methyl sulfa nyl]methyl)propyl]amino}-1 H-quinolin-2-one 5-{(1S, 2R)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2- ([ethyl sulfanyl]methyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2S)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2S)[1 -(2-C h lo ro-3-fl uo ro-4-m ethoxyphe nyl)-2-(ethoxym ethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 25)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2S)[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 2R)[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-2-(chloromethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1 H-quinolin-2-one 5-{(1S, 25)[3,3,3-trifluoro-2-hydroxy-2-([methoxymethyl)-1-phenylpropyl]amino}-1H-quinolin-1-one and their salts, solvates or salts of solvates.
11 Compounds of general formula I, wherein at least one of R1, R2 or R3 are different from hydrogen are one preferred embodiment of the invention.

Compounds of general formula I according to claims 1-7, wherein at least one of R1, R2 or R3 is different from hydrogen are one preferred embodiment of the invention.

In another embodiment two of R', R2 or R3 according to claim 1 or claims 1-7 are different from hydrogen.

In yet a further embodiment all three R1, R2 or R3 according to claim 1 or claims 1-7 are different from hydrogen.

In one aspect of the invention the alkyl groups of the compounds of formula (I) have 1-5 carbon atoms.

In another aspect the alkyl groups of the compounds of formula (I) have 1-3 carbon atoms.

The quinolon ring of formula I can be substituted by a radical R4 selected from the group consisting of halogen, hydroxy, (C1-C5)-alkyl, (C1-C5)alkoxy, (C1-C5)-alkylthio, (C1-C5)-perfluoroalkyl, cyano, nitro, NR7R8 COOR9 (CO)NR7R8 or a (C1-C5-alkylene)-O-(CO)-(C1_C5)alkyl group, preferably R4 is selected from the group alkyl, C1-C3-alkoxy, hydroxy, halogen. In another aspect of the invention R4 is selected from the group hydrogen, C1-C3-alkyl, halogen, hydroxy, preferably from hydrogen or halogen, more preferably from hydrogen, chlorine or fluorine.
Another subject of the invention are compounds according to formula 1 wherein R4 is hydrogen or fluorine.

Yet another subject of the invention are compounds according to formula 1 wherein R4 is fluorine.

More particularly compounds according to formula I wherein R4 is a 7-fluoro-substituent or hydrogen and at least one of R1, R2 and R3 is selected from chlorine, fluorine, methoxy, hydroxy, R5 is selected from S-CH2-CH3, -O-CH2-CH3, -S-CH3, CH3 -, N(CH3)2, -OH and -Cl.
12 Another aspect of the invention are compounds according to formula I wherein R4 is a 7-fluoro-substituent or hydrogen and at least one of R1, R2 and R3 is selected from chlorine, fluorine, methoxy, R5 is selected from S-CH2-CH3, -O-CH2-CH3, -S-CH3, -O-CH3 -, -OH and -CI.A preferred aspect of the invention are the subcombinations of all the residues as disclosed in the examples.

One aspect of the invention are compounds of general formula I, wherein the phenyl group is substituted with 1-3 of the same or different substituents R1, R2 and R3. R1 and R2 are independently of one another, mean a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C1o)-alkyl group, an optionally substituted (C1-C10)-alkoxy group, a (C1-C10)-alkylthio group, a (C1-C5)-perfluoroalkyl group, a cyano group, a nitro group, or R1 and R2 together mean a group that is selected from the groups -O-(CH2)p O-, -O-(CH2)p CH2-, -O-CH=CH-, -(CH2)p+2-, -NH-(CH2)p+1, -N(C1-C3-alkyl)-(CH2)p+1, and -NH-N=CH-, whereby p = 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring-carbon atoms, or R1 and R2 are NR6R7, whereby R6 and R7, independently of one another, mean hydrogen, C1-C5-alkyl or (CO)-(C1-C5)-alkyl.
The third substituent R3 means a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-C10)-alkyl group, a (C1-C10)-alkoxy group, a (C1-C10)-alkylthio group, or a (C1-C5)-perfluoroalkyl group.

In another aspect any other phenyl group may be substituted by a group selected from ,C1-C3-alkoxy, hydroxy, and halogen, in particular methoxy, hydroxy, fluorine, chlorine, or bromine.

In another aspect of the invention R5 of compounds of claim 1-6 selected from -(C1-C10)-alkyl, which may be optionally partially or completely halogenated, -(C2-C10)-alkenyl, -(C2-C10)-alkynyl, (C3-C7)cycloalkyl-(C1-C8)alkyl, (C3-C7)cycloalkyl-(C2-C8)alkenyl, (C3-C7)cycloalkyl-(C1-C8)alkynyl, heterocyclyl-(C1-C8)alkyl, heterocyclyl-(C2-C8)alkenyl, heterocyclyl-(C2-C8)alkynyl -R8, R8-(C1-C8)alkyl, R8-(C2-C8)alkenyl, R8-(C2-C8)alkynyl, -S-(C1-C10)alkyl, -S02-(C1-C10)alkyl-S-R8, -S02-R8, -CN, -Hal, -O-(C1-C10)alkyl, -NR6R7 (wherein R6, R7 have the meaning defined above), -O-R8 and -OH with the exception of -CH(CH3)2, or -C(CH3)=CH2. In yet another aspect R5 is selected from the group consisting of -(C1-C10)-alkyl, which may be optionally partially or completely halogenated, -(C2-C10)-alkenyl, -(C2-C1o)-alkynyl,
13 -(C3-C7)cycloalkyl-(C1-C8)alkyl, -(C3-C7)cycloalkyl-(C2-C8)alkenyl, -S-(C1-C10)-alkyl, -S02-(C1-C10)-alkyl, -CN, -Hal, -O-(C1-C10)-alkyl, -NR6R7 (wherein R6, R7 have the meaning defined above), -OH with the exception of -CH(CH3)2, or -C(CH3)=CH2., preferably R5 is -OH, Cl, -S-CH3, -S-CH2-CH3, -S-CH2-CH2-CH3, -O-CH3, -O-CH2-CH3, -O-CH2-CH2-CH3, N(CH3)2, NHCH3 with the exception of -CH(CH3)2, or -C(CH3)=CH2, R5 is most preferably is -OH, -S-CH3, -S-CH2-CH3, -O-CH3, -O-CH2-CH3 or N(CH3)2.

In another aspect of the invention R5 of compounds of claim 1-6 selected from (C3-C7)cycloalkyl-(C1-C8)alkyl, (C3-C7)cycloalkyl-(C2-C8)alkenyl, (C3-C7)cycloalkyl-(C1-C8)alkynyl, heterocyclyl-(C1-C8)alkyl, heterocyclyl-(C2-C8)alkenyl, heterocyclyl-(C2-C8)alkynyl -R8, R8-(C1-C8)alkyl, R8-(C2-C8)alkenyl, R8-(C2-C8)alkynyl, -S-(C1-C10)alkyl, -SO2-(C1-C10)alkyl-S-R8, -S02-R8, -CN, -Hal, -O-(C1-C10)alkyl, -NR6R7 (wherein R6, R7 have the meaning defined above), -O-and -OH.

In yet another aspect R5 of compounds of claim 1-6 is selected from the group consisting of -(C3-C7)cycloalkyl-(C1-C8)alkyl, -(C3-C7)cycloalkyl-(C2-C8)alkenyl, -S-(C1-C10)-alkyl, -SO2-(C1-C10)-alkyl, -CN, -Hal, -O-(C1-C10)-alkyl, -NR6R7 (wherein R6, R7 have the meaning defined above), -OH; preferably R5 is -OH, Cl, -S-CH3, -S-CH2-CH3, -S-CH2-CH2-CH3, -O-CH3, -O-CH2-CH3, -O-CH2-CH2-CH3, N(CH3)2, NHCH3, R5 is most preferably is -OH, -S-CH3, -S-CH2-CH3, -O-CH3, -O-CH2-CH3 or N(CH3)2.

Another aspect of the invention relates to compounds according to claims 1-6 wherein R5 selected from -R8, -S-(C1-C10)-alkyl, -SO2-(C1-C10)-alkyl, -S-R8, -S02-R8, -CN, -Hal, -O-(C1-C10)-alkyl, -NR6R7, wherein R6, R7 have the meaning defined in claim 1, -O-R8 or-OH.

Another aspect of the invention relates to compounds according to claims 1-6 wherein R5 selected from -S-(C1-C10)-alkyl, -S02-(C1-C10)-alkyl, -CN, -Hal, -O-(C1-C10)-alkyl, -NR6R7, wherein R6, R7 have the meaning defined in claim 1, or-OH.
14 Another aspect of the invention relates to compounds according to claims 1-6 wherein R5 selected from -S-(C1-Cio)-alkyl, -O-(C1-Clo)-alkyl, -NR6R7, wherein R6, R7 have the meaning defined in claim 1, or-OH.

One aspect of the invention are compounds according to claims 1-7, wherein R5 is not -(Ci-Cio)-alkyl or -(C2-C1o)-alkenyl.

Another aspect of the present invention are compounds of general formula I
according to claims 1-7, wherein R5 is not -(Ci-C1o)-alkyl or -(C2-Cio)-alkenyl and from R1/R2/R3 at least two are different from hydrogen or R1/R2/R3 all are different from hydrogen and R4 is halogen. In addition, the invention relates to the use of the compounds of general formula I for the production of pharmaceutical agents as well as their use for the production of pharmaceutical agents for treating inflammatory diseases.

Definitions Unless otherwise notifed the term "alkyl" refers to a straight or branched, substituted or unsubstituted chain. For example, the term propyl comprises propyl and 1SO-propyl, the term butyl comprises butyl, 'SO-butyl and tell.-butyl.

The alkyl groups can be straight-chain or branched and stand e.g. for a methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl or n-pentyl group, or a 2,2-dimethylpropyl, 2-methylbutyl or 3-methylbutyl group. A methyl or ethyl group is preferred. They can optionally be substituted by 1-3 hydroxy groups, cyano groups, halogen, 1-3 C1-C5-alkoxy groups, and/or 1-3 COO(C1-C10-alkyl or benzyl) groups.
Preferred are hydroxy groups. The total number of substituents depends on the number of carbon atoms of the chain. Usually the number of substituents does not exceed the number of carbon atoms except for halogen which leads at a maximum number of substituents to e.g. perfluorated alkyl groups.

For a partially or completely fluorinated C1-C3-alkyl group, the following partially or completely fluorinated groups are considered: fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, 1,1-difluoroethyl, 1,2-difluoroethyl, 1,1,1-trifluoroethyl, tetrafluoroethyl, and pentafluoroethyl. Of the latter, the trifluoromethyl group or the pentafluoroethyl group is preferred.

The Cl-C5-alkoxy groups in R1, R2, R3 and R5 can be straight-chain or branched and stand for a methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy or n-pentoxy, 2,2-dimethylpropoxy, 2-methylbutoxy or 3-methylbutoxy group. A methoxy or ethoxy group is preferred. They can optionally be 5 substituted by C1-C5-alkyl groups, cyano groups or halogen The Cl-C5-alkylthio groups can be straight-chain or branched and stand for a methylthio, ethylthio, n-propylthio, iso-propylthio, n-butylthio, iso-butylthio, tert-butylthio or n-pentylthio, 2,2-dimethylpropylthio, 2-methylbutylthio or 3-methylbutylthio group. A methylthio or ethylthio group is preferred.

10 The term halogen atom, Hal or halogen means a fluorine, chlorine, bromine or iodine atom. Preferred is a fluorine, chlorine or bromine atom.

The NR6R7 group includes, for example, NH2, N(H)CH3, N(CH3)2, N(H)(CO)CH3, N(CH3)(CO)CH3, N[(CO)CH3]2, N(H)CO2CH3, N(CH3)CO2CH3, or N(CO2CH3)2.
15 The term C2-C8-alkenyl is a straight or branched, substituted or unsubstituted, chain including isomers having an E- or Z-configurated double bond such as e.g.
vinyl, propen-1-yl, propen-2-yl (Allyl), but-1-en-1-yl, but-1-en-2-yl, but-2-en-1-yl, but-2-en-2-yl, 2-methyl-prop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, but-1-en-3-yl, but-3-en-1-yl. If the alkenyl residue is placed between two other moieties the term alkenyl means alkenylene such as e.g. vinylene, propen-1-ylene, propen-2-ylene (Allylen), but-1-en-1-ylene, but-1-en-2-ylene, but-2-en-1-ylene, but-2-en-2-ylene, 2-methyl-prop-2-en-1-ylene, 2-methyl-prop-1-en-1-ylene, but-1-en-3-ylen, but-3-en-1-ylene.

The term C2-C8-alkynyl stands for a straight or branched chain e,g, -C=CH, -CH2-C=CH, -C=C-CH3, -CH(CH3)-C=CH, -C-C-CH2(CH3), -C(CH3)2-C=CH, -C-C-CH(CH3)2, -CH(CH3)-C-C-CH3, , -CH2-C=C-CH2(CH3) or, if the alkynyl residue is placed between two other moieties the term alkynyl means alkynylene such as e.g. -C=C-, -CH2-C=C-, -C=C-CH2-, -CH(CH3-C=C-, -C=C-CH(CH3)-, -C(CH3)2-C=C-, -C=C-C-(CH3)2-, -CH(CH3)-C=C-CH2-, -CH2-C=C-CH (CH3)-.
16 The term C3-C7-cycloalkyl means a substituted or unsubstituted group selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl.
The possible substitutents may be selected from hydroxy, halogen, (C1-C5)-alkyl, (C1-C5)-alkoxy, NR4R5, COO(C1-C5)-alkyl, CHO, cyano.

The term C3-C7-cycloalkyl-(C1-C1o)-alkyl- means e.g. -(CH2)-cycloalkyl, -(C2H4)-cycloalkyl, -(C3H6)-cycloalkyl, -(C4H8)-cycloalkyl, -(C5H10)-cycloalkyl whereby the cycloylkyl stand for e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl.

The term C3-C7-cycloalkyl-(C2-C8)-alkenyl means e.g. -(CH=CH)-cycloalkyl, -[C(CH3)=CH]-cycloalkyl, -[CH=C(CH3)]-cycloalkyl, -(CH=CH-CH2)-cycloalkyl, -(CH2-CH=CH)-cycloalkyl, -(CH=CH-CH2-CH2)-cycloalkyl, -(CH2-CH=CH-CH2)-cycloalkyl, -(CH2-CH2-CH=CH)-cycloalkyl, -(C(CH3)=CH-CH2)-cycloalkyl, -(CH=C(CH3)-CH2)-cycloalkyl whereby the term cycloalkyl is defined above..

The term heterocyclyl means e.g. piperidinyl-, morpholinyl-, thiomorpholinyl-, piperazinyl-, tetrahydrofuranyl-, tetrahydrothienyl-, imidazolidinyl- or pyrrolidinyl-whereby the heterocyclyl group may be bound via any possible ring atom..
The heterocyclyl group may be substituted by C1-C5-alkyl (optionally substituted), hydroxy-, C1-C5-alkoxy-, NR4R5-, halogen, cyano-, COORS-, CHO-. If possible these substitutens may also be bound to one of the free nitrogen atoms if any. N-oxides are also included in the definition.

The term heterocyclyl-(C1-C10)-alkenyl- means an alkylene group as defined above which is connected to the heterocyclyl group which also is already defined above.

The term heterocyclyl-(C2-C8)-alkenyl- means an alkylenylene group as defined above which is connected to the heterocyclyl group which also is already defined above.

The term aryl in the sense of the invention means aromatic or partially aromatic carbocyclic rings having 6 to 14 carbon atoms, e.g. phenyl and which may
17 also may have a condensed a second or third ring such as e.g. napthyl or anthranyl.
Further examples are phenyl, naphthyl, tetralinyl, anthranyl, benzoxazinone, dihydroindolone, indanyl, and indenyl.
The aryl groups may be substituted at any position leading to a stable molecule by one or several substitutents, e.g. 1-3 substitutents, such as e.g. hydroxy, halogen, C1-C5-alkyl, C1-C5-alkoxy, cyano, CF3, nitro, COO(C1-C5-alkyl or benzyl) or a heteroaryl group , preferably by 1-3 C1-C5-alkyl groups, hydroxyl, halogen, cyano or C1-C5-alkoxy.
The optionally substituted phenyl group is one aspect of the invention. Yet another aspect are the compounds of formula I whereby R8 is not phenyl.

The term heteroaryl means an aromatic ring system having 1-3 heteroatoms selected from nitrogen, oxygen or sulfur, for five membered rings the maximum number of heteroatoms is three whereby only two oxygen or sulfur atoms are allowed provided that these two are not directly bound to each other.
Possible heteroaryl rings are e.g. thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, benzofuranyl, benzothienyl, benzothiazol, benzoxazolyl, benzimidazolyl, indazolyl, indolyl, isoindolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, azaindolizinyl-,benzopyridyl, benzopyridazinyl, benzopyrimidinyl, benzopyrazinyl, benzotriazinyl, quinolyl, isoquinolyl, phthalidyl-, thiophthalidyl, indolonyl-, dihydroindolonyl-, isoindolonyl-, dihydroisoindolonyl-, benzofuranyl- or benzimidazolyl.

The compounds of the present invention can exist in stereoisomeric forms such as enantiomers of diastereoisomers depending on their structure and residues as defined in formula 1. In one aspect of the invention therefore all these enantiomers, diastereoisomers or mixtures thereof are encompassed. The isolation of enantiomerically or diastereomerically pure isomers can be done by methods of the state of the art, e.g. using column chromatography with a chiral solid phase.

Should it be possible that the compounds of the invention also exist in tautomeric forms these are also an aspect of the present invention.

In one aspect of the invention all compounds defined in formula I as well as their salts, solvates and solvates of salts are encompassed,. especially the salts, solvates and salts of solvates of the compounds disclosed in the examples are one
18 aspect of the invention as long as the disclosed compounds themselves are not already salts, solvates or solvates of the salts.

Salts in the sense of the present invention are not only physiologically unobjectable salts but also salts which might be objectable for pharmaceutical use but which are useful e.g. during the process of isolation or purification.

The term physiologically unobjectable salts includes addition salts of mineral acids, carbonic acids, sulfonic acids, e.g. salts of hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluolsulfonic acid, benzenesulfonic acid, naphthalinesulfonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, pivalic acid, maleic acid, succinic acid and benzoic acid.

In addition the term physiologically unobjectable salts includes salts of commonly suitable bases, e.g. salts of alkalimetall (e.g.. sodium- and potassium salts), alkaline earth salts (e.g. calcium- and magnesium salts) and ammonium salts, derivatized from NH3 or organic amines with 1 to 16 carbon atoms, e.g. ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, prokaine, dibenzylamine, N-methylmorpholin, arginin, lysin, ethylendiamine and N-methylpiperidin.

Solvates in the sense of the invention are such forms of the compounds of the present combinations which build complexes by coordination of solvent molecules in a liquid or a solid phase. Hydrates are special forms of a solvate wherein water molecules are coordinated.

Salts in the sense of the present invention are not only physiologically unobjectable salts but also salts which might be objectable for pharmaceutical use but which are useful e.g. during the process of isolation or purification.
19 The compounds can be produced by the two processes that are described below (a-b).

Process a) step a) I \ \

H

H
R H R' \ 0 (III) 2 \ N NH

R3 0 Ti(OR)4 and/or acid R3 0 (II) (IV) Benzaldehydes of type (II) can be condensed with substituted aminoquinolones of type (III) to imines of type (IV) using Lewis acids, preferably titanium alcoholates Ti(OR)4 wherein R is C1-C4-alkyl, such as e.g. tetraethyl orthotitanate or tetra tert.
butyl orthotitanate and/or acidic conditions, e.g. organic acids such as acetic acid as reagents. Suitable solvents are e.g. toluene, 1,4-dioxane or mixtures thereof.

Step b) R' I M R' R2 e N NH 2 NH
R3 / nBuLi, -80 to -100 C 3 O R
R
a H 0 (IV) (VI) Step c) R R5 Met 1 z NH R

R3 I \ \ R

H R H O
(VI) (I) Imines of type (IV) are treated at low temperatures of -80 to -100 C with the lithiated epoxide (V) to yield compounds of type (VI). Suitable solvents are e.g.
5 tetrahydrofurane, hexane, diethylether or mixtures thereof. The epoxides (VI) can be opened by nucleophiles of type R5-Met to deliver compound (I). Met means metal and includes alkalimetals e.g. sodium or lithium, alkaline earth metals such as e.g.
magnesium, caesium; aluminium, copper, silicon or tin (Sn) which bind the nucleophilic residue R5 of R5-Met depending on their valence and according to the 10 knowledge of a person with ordinary skill. The resulting possible nucleophilic reagents R5-Met are e.g. alkylcuprates, vinylcuprates, thioles, allylsilanes, vinylsilanes, vinylstannanes, grignard compounds whereby R5 is defined as in claim 1, which react in the presence of Lewis acids like e.g. BF3 or AIMe3, AICI3.
Suitable solvents are e.g. diethylether, dimethylformamide, tetrahydrofurane. The epoxides 15 (VI) can also be opened directly by cyanides, amines, alcoholates, thioalcoholates, halogenides and even water or Cs2CO3/H2O in the presence of bases or strong protic acids.
Suitable bases in the sense of the invention are e.g. Cs2CO3, K2CO3 or NaOH
Suitable strong protic acids are e.g. HCIO4, HCI or HBr.
20 Process b) step a) N/ <t-' CF CF3 R 0 (V) 0 RZ \ R2 \
nBuLi, -80 to -100 C R3
21 (VII) (VIII) Methoxymethylamides of type (VII) are treated at low temperatures of -80 to -with the lithiated epoxide (V) to yield compounds of type (VIII). Compounds of formula (VII) are commercially available or can be synthesized according to Branca et al, Chimia 49, 10; 1995, 381-385.

step b) R OH
CF3 Rs Met CF3 -R

R
(VIII) (IX) The epoxides (VIII) can be opened by nucleophils of type R5-Met to deliver compound (IX). Possible nucleophiles are alkylcuprates, vinylcuprates, thioles, allylsilanes, vinylsilanes, vinylstannanes, grignard compounds, in the presence of Lewis acids like BF3 or AIMe3, AICI3, or directly by cyanides, amines, alcohols, thioalcohols, halogenides and water in the presence of bases or strong protic acids.
Step c) Rs \ \ Rs H
1 (III) R2 O 1. ::: HOAc R 2 2. on R3 R H O
(IX) (I)
22 Ketones of type (IX) can be condensed with substituted aminoquinolones of type (III) to imines and subsequently or simultaneously reduced to the aminoalcohol I by a reductive amination using complex hydrides like e.g. NaBH4 or LiAIH4 (Katritzky et al.
J.Org.Chem. 1995, 60, 7631-7640) or hydrogen in the presence of catalytic amounts of palladium or platinum or by application of an asymmetric organocatlytic transfer hydrogenation (List et al. Angew. Chem. 2005, 117, 7590-7593).

This processes described above can be perfomed enantioselectively by use of enantiopure epoxide of formula (V) to yield enantiopure compounds of formula (VI), (VIII), (IX) and (I). The last reductive step of b) can be performed in a diastereoselective manner to yield enantiopure compound I when enantiopure compound IX is used as starting material.
Alternatively during the process of the production of the compounds of formula I at different stages purification for obtaining enantiomerically or diastereomerically pure intermediates may be performed e.g. intermediates of formula VI, VIII, IX can be purified at the step when they are obtained or compounds of formula I can be purified to obtain enantiomerically or diastereomerically pure end products after the complete reaction cascade. Examples for methods for obtaining enantiopure (enantiomerically pure) compounds are described below. The separation of optical isomers can be performed by separation of one or more of the intermediates and/or separation of the end products. Usually separation of intermediates and separation of end products are alternatives as long as no racemisation had taken place during the production process.
If the compounds according to the invention are present as racemic mixtures, they can be separated into pure, optically active forms according to the methods of racemate separation that are familiar to one skilled in the art. For example, the racemic mixtures can be separated by chromatography on an even optically active carrier material (CHIRALPAK AD ) into the pure isomers. It is also possible to use chiral auxiliary agents as optically pure acids. For that purpose the free hydroxy group is esterified to yield a racemic compound of general formula I with an optically active acid and to separate the diastereoisomeric esters that are obtained by fractionated crystallization or by chromatography, and to saponify the separated esters in each case to the optically pure isomers. As an optically active acid, for example, mandelic acid, camphorsulfonic acid or tartaric acid can be used.
23 Thus one aspect of the invention is the process of obtaining compounds of formula I in diastereomerically pure form, optionally using chromatography with columns containing chiral material or using chiral auxiliary agents.

Each of the intermediates of the synthesis of the compounds of formula I are one aspect of the present invention as well as especially their use for the synthesis of the compounds of formula I. A specific aspect of the invention are the concrete intermediates as used for the synthesis of the compounds of the examples, either as racemate or in their enantiomerically (having one chiral center) or diastereomerically (having two chiral centers) pure form.

The binding of the substances to the glucocorticoid receptor (GR) and other steroid hormone receptors (mineral corticoid receptor (MR), progesterone receptor (PR) and androgen receptor (AR)) is examined with the aid of recombinantly produced receptors. Cytosol preparations of Sf9 cells, which had been infected with recombinant baculoviruses, which code for the GR, are used for the binding studies.
In comparison to reference substance [3H]-dexamethasone, the substances show a high to very high affinity to GR. IC50(GR) = 6.8 nM, IC50(GR) = 5.7 nM and IC50(GR) _ 3.1 nM and IC50(GR) = 7.1 nM was thus measured for the compound from Examples 1, 4, 5 and 7 respectively.

As an essential, molecular mechanism for the anti-inflammatory action of glucocorticoids, the GR-mediated inhibition of the transcription of cytokines, adhesion molecules, enzymes and other pro-inflammatory factors is considered. This inhibition is produced by an interaction of the GR with other transcription factors, e.g., AP-1 and NF-kappa-B (for a survey, see Cato, A. C. B., and Wade, E., BioEssays 18, 378, 1996).

The compounds of general formula I according to the invention inhibit the secretion of cytokine IL-8 into the human monocyte cell line THP-1 that is triggered by Iipopolysaccharide (LPS). The concentration of the cytokines was determined in the supernatant by means of commercially available ELISA kits. The compound from Examples 4, 5, 7 and 8 showed an inhibition IC50(IL8) = 0.61 nmol, IC50(IL8) =
0.19 nmol, IC50(IL8) = 0.44 nmol and IC50(IL8) = 3.1 nmol with efficacies of 97%, 98%, 98%
and 80% respectively in comparison with dexamethasone as reference.
24 The anti-inflammatory action of the compounds of general formula I was tested in the animal experiment by tests in the croton oil-induced inflammation in rats and mice (J. Exp. Med. 1995, 182, 99-108). To this end, croton oil in ethanolic solution was applied topically to the animals' ears. The test substances were also applied topically or systemically at the same time or two hours before the croton oil.
After 16-24 hours, the ear weight was measured as a yardstick for inflammatory edema, the peroxidase activity as a yardstick for the invasions of granulocytes, and the elastase activity as a yardstick for the invasion of neutrophilic granulocytes. In this test, the compounds of general formula I inhibit the three above-mentioned inflammation parameters both after topical administration and after systemic administration.

One of the most frequent undesirable actions of a glucocorticoid therapy is the so-called "steroid diabetes" [cf., Hatz, H. J., Glucocorticoide:
Immunologische Grundlagen, Pharmakologie and Therapierichtlinien [Glucocorticoids:
Immunological Bases, Pharmacology and Therapy Guidelines], Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1998]. The reason for this is the stimulation of gluconeogenesis in the liver by induction of the enzymes responsible in this respect and by free amino acids, which are produced from the degradation of proteins (catabolic action of glucocorticoids). A key enzyme of the catabolic metabolism in the liver is tyrosinamino transferase (TAT). The activity of this enzyme can be determined from liver homogenates by photometry and represents a good measurement of the undesirable metabolic actions of glucocorticoids. To measure the TAT induction, the animals are sacrificed 8 hours after the test substances are administered, the livers are removed, and the TAT activity is measured in the homogenate. In this test, at doses wherein they have an anti-inflammatory action, the compounds of general formula I induce little or no tyrosinamino transferase.
Because of their anti-inflammatory and, in addition, anti-allergic, immunosuppressive and antiproliferative action, the compounds of general formula I
according to the invention can be used as medications for treatment or prophylaxis of the following pathologic conditions in mammals and humans: In this case, the term "DISEASE" stands for the following indications:

(i) Lung diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Chronic, obstructive lung diseases of any origin, primarily bronchial asthma 5 - Bronchitis of different origins - Adult respiratory distress syndrome (ARDS), acute respiratory distress syndrome - Bronchiectases - All forms of restrictive lung diseases, primarily allergic alveolitis, 10 - All forms of pulmonary edema, primarily toxic pulmonary edema; e.g., radiogenic pneumonitis - Sarcoidoses and granulomatoses, especially Boeck's disease (ii) Rheumatic diseases/autoimmune diseases/joint diseases, which coincide with inflammatory, allergic and/or proliferative processes:

15 - All forms of rheumatic diseases, especially rheumatoid arthritis, acute rheumatic fever, polymyalgia rheumatica, Behget's disease - Reactive arthritis - Inflammatory soft-tissue diseases of other origins - Arthritic symptoms in the case of degenerative joint diseases 20 (arthroses) - Traumatic arthritides - Vitiligo - Collagenoses of any origin, e.g., systemic lupus erythematodes, sclerodermia, polymyositis, dermatomyositis, Sjogren's syndrome, Still's syndrome, Felty's syndrome - Sarcoidoses and granulomatoses - Soft-tissue rheumatism (iii) Allergies or pseudoallergic diseases, which coincide with inflammatory and/or proliferative processes:

- All forms of allergic reactions, e.g., Quincke's edema, hay fever, insect bites, allergic reactions to pharmaceutical agents, blood derivatives, contrast media, etc., anaphylactic shock, urticaria, allergic and irritative contact dermatitis, allergic vascular diseases - Allergic vasculitis (iv) Vascular inflammations (vasculitides) - Panarteritis nodosa, temporal arteritis, erythema nodosum - Polyarteris nodosa - Wegner's granulomatosis - Giant-cell arteritis (v) Dermatological diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Atopic dermatitis (primarily in children) - All forms of eczema, such as, e.g., atopic eczema (primarily in children) - Rashes of any origin or dermatoses - Psoriasis and parapsoriasis groups - Pityriasis rubra pilaris - Erythematous diseases, triggered by different noxae, e.g., radiation, chemicals, burns, etc.

- Bullous dermatoses, such as, e.g., autoimmune pemphigus vulgaris, bullous pemphigoid - Diseases of the lichenoid group, - Pruritis (e.g., of allergic origin) - Seborrheal eczema - Rosacea group - Erythema exudativum multiforme - Balanitis - Vulvitis - Manifestation of vascular diseases - Hair loss such as alopecia areata - Cutaneous lymphoma (vi) Kidney diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Nephrotic syndrome - All nephritides, e.g., glomerulonephritis (vii) Liver diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Acute liver cell decomposition - Acute hepatitis of different origins, e.g., viral, toxic, pharmaceutical agent-induced - Chronic aggressive hepatitis and/or chronic intermittent hepatitis (viii) Gastrointestinal diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Regional enteritis (Crohn's disease) - Colitis ulcerosa - Gastritis - Reflux esophagitis - Ulcerative colitis of other origins, e.g., native sprue (ix) Proctologic diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Anal eczema - Fissures - Hemorrhoids - Idiopathic proctitis (x) Eye diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Allergic keratitis, uveitis, iritis - Conjunctivitis - Blepharitis - Optic neuritis - Chorioiditis - Sympathetic ophthalmia (xi) Diseases of the ear-nose-throat area, which coincide with inflammatory, allergic and/or proliferative processes:

- Allergic rhinitis, hay fever - Otitis externa, e.g., caused by contact dermatitis, infection, etc.
- Otitis media (xii) Neurological diseases, which coincide with inflammatory, allergic and/or proliferative processes:

- Cerebral edema, primarily tumor-induced cerebral edema - Multiple sclerosis - Acute encephalomyelitis - Meningitis - Various forms of convulsions, e.g., infantile nodding spasms - Acute spinal cord injury - Stroke (xiii) Blood diseases, which coincide with inflammatory, allergic and/or proliferative processes, such as, e.g.: M. Hodgkins or Non-Hodgkins lymphomas, thrombocythemias, erythrocytoses - Acquired hemolytic anemia - Idiopathic thrombocytopenia (xiv) Tumor diseases, which coincide with inflammatory, allergic and/or proliferative processes, such as, e.g.: carcinomas or sarcomas - Acute lymphatic leukemia - Malignant lymphoma - Lymphogranulomatoses - Lymphosarcoma - Extensive metastases, mainly in breast, bronchial and prostate cancers (xv) Endocrine diseases, which coincide with inflammatory, allergic and/or 5 proliferative processes, such as, e.g.:
- Endocrine orbitopathy - Thyreotoxic crisis - De Quervain's thyroiditis - Hashimoto's thyroiditis 10 - Basedow's disease - Granulomatous thyroiditis - Lymphadenoid goiter (xvi) Organ and tissue transplants, graft-versus-host disease (xvii) Severe shock conditions, e.g., anaphylactic shock, systemic inflammatory 15 response syndrome (SIRS) (xviii) Substitution therapy in:

- Innate primary suprarenal insufficiency, e.g., congenital adrenogenital syndrome - Acquired primary suprarenal insufficiency, e.g., Addison's disease, 20 autoimmune adrenalitis, meta-infective tumors, metastases, etc.

- Innate secondary suprarenal insufficiency, e.g., congenital hypopituitarism - Acquired secondary suprarenal insufficiency, e.g., meta-infective tumors, etc.

(xix) Emesis, which coincide with inflammatory, allergic and/or proliferative processes:

- e.g., in combination with a 5-HT3 antagonist in cytostatic-agent-induced vomiting (xx) Pains of inflammatory origins, e.g., lumbago (xxi) Other different stages of disease including diabetes type I (insulin-dependent diabetes), osteoarthritis, Guillain-Barre syndrome, restenoses after percutaneous transluminal angioplasty, Alzheimer's disease, acute and chronic pain, arteriosclerosis, reperfusion injury, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.

Moreover, the compounds of general formula I according to the invention can be used for treatment and prophylaxis of additional pathologic conditions that are not mentioned above, for which synthetic glucocorticoids are now used (see in this respect Hatz, H. J., Glucocorticoide: Immunologische Grundlagen, Pharmakologie and Therapierichtlinien, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1998).

All previously mentioned indications (i) to (xx) are described in more detail in Hatz, H. J., Glucocorticoide: Immunologische Grundlagen, Pharmakologie and Therapierichtlinien, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1998.

All of the diseases mentioned above do have in common that they are thought to be caused by inflammatory, allergic, immunosuppressive or antiproliferative processes. Thus the invention also relates to methods for treatment of inflammatory, allergic, immunosuppressive or antiproliferative diseases and the use of the compounds of formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment thereof. One special aspect is the treatment of inflammatory diseases.

The glucocorticoid receptor is known to be involved in the process of inflammation Thus another aspect of the invention is a method of treating a glucocorticoid receptor mediated disease state in a mammal, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof and the use of a compound or formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1-6, for the manufacture of a medicament for use in the treatment of a glucocorticoid receptor mediated disease state.

Another aspect of the invention are compounds of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1-6 for use in therapy.
For the therapeutic actions in the above-mentioned pathologic conditions, the suitable dose varies and depends on, for example, the active strength of the compound of general formula I, the host, the type of administration, and the type and severity of the conditions that are to be treated, as well as the use as a prophylactic agent or therapeutic agent.

In addition, the invention provides:

(i) The use of one of the compounds of formula I according to the invention or mixture thereof for the production of a medication for treating a DISEASE;

Claims (21)

Claims
1. Compounds of general formula I

R1 and R2 independently of one another, mean a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C10)-alkyl group, an optionally substituted (C1-C10)-alkoxy group, a (C1-C10)-alkylthio group, a(C1-C5)-perfluoroalkyl group, a cyano group, a nitro group, or R1 and R2 together mean a group that is selected from the groups -O-(CH2)p-O-, -O-(CH2)p CH2-, -O-CH=CH-, -(CH2)p+2-, -NH-(CH2)p+1, -N(C1-C3-alkyl)-(CH2)p+1, and -NH-N=CH-, whereby p = 1 or 2, and the terminal oxygen atoms and/or carbon atoms and/or nitrogen atoms are linked to directly adjacent ring-carbon atoms, or NR6R7, whereby R6 and R7, independently of one another, mean hydrogen, C1-C5-alkyl or (CO)-(C1-C5)-alkyl, R3 means a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-C10)-alkyl group, a(C1-C10)-alkoxy group, a(C1-C10)-alkylthio group, or a (C1-C5)-perfluoroalkyl group, R4 means a hydrogen, halogen, hydroxy, (C1-C5)-alkyl, P-C5)alkoxy, (C1-C5)-alkylthio, (C1-C5)-perfluoroalkyl, cyano, nitro, NR6R7, COOR9, (CO)NR6R7 or a (C1-C5-alkylene)-O-(CO)-(C1-C5)alkyl group R5 means a group selected from -(C1-C10)alkyl, which may be optionally partially or completely halogenated -(C2-C10)alkenyl, -(C2-C10)alkynyl, (C3-C7)cycloalkyl-(C1-C8)alkyl, (C3-C7)cycloalkyl-(C1-C8)alkyenyl, (C3-C7)cycloalkyl-(C2-C8)alkynyl, heterocyclyl-(C1-C8)alkyl, heterocyclyl-(C1-C8)alkenyl, heterocyclyl-(C2-C8)alkynyl, -R8, R8-(Cl -C8)alkyl, R8-(C2-C8)alkenyl, R8-(C2-C8)alkynyl, -S-(C1-C10)-alkyl, -S02-(C1-C10)-alkyl -S-R8, -SO2-R8, -CN
-Hal, -O-(C1-C10)-alkyl, -NR6R7 wherein R6, R7 have the meaning defined above -O-R8, -OH, with the exception of -CH(CH3)2, or -C(CH3)=CH2, R 8 means an aryl group which may optionally be substituted by 1-3 hydroxy, halogen, C1-C5-alkyl, C1-C5-alkoxy, cyano, CF3, nitro, COO(C1-C5-alkyl) or C(O)OCH2-phenyl or a heteroaryl group whereby the heteroaryl group may contain 1-3 hetero atoms which may optionally be substituted by 1-3 alkyl groups, hydroxy, halogen, cyano or C1-C5-alkoxy groups.
and their salts, solvates or salts of solvates.
2. Compounds of general formula I according to claim 1, wherein R1 and R2 independently of one another, mean a hydrogen atom, a hydroxy group, a halogen atom, an optionally substituted (C1-C10)-alkyl group, an optionally substituted (C1-C10)-alkoxy group, a (C1-C5)-perfluoroalkyl group, a cyano group, or NR6R7, whereby R6 and R7, independently of one another, mean hydrogen, C1-C5-alkyl or (CO)-(C1-C5)-alkyl, R3 means a hydrogen atom, a hydroxy group, a halogen atom, a cyano group, an optionally substituted (C1-C10)-alkyl group, a (C1-C10)-alkoxy group, or a (C1-C5)-perfluoroalkyl group, R4 means hydrogen, C1-C3-alkyl, C1-C3-alkoxy, hydroxy, halogen, R5 means a group selected from -(C1-C10)-alkyl, which may be optionally partially or completely halogenated -(C2-C10)-alkenyl, -(C2-C10)-alkynyl, -(C3-C7)cycloalkyl-(C1-C8)alkyl, -(C3-C7)cycloalkyl-(C2-C8)alkenyl, -S-(C1-C10)-alkyl, -SO2-(C1-C10)-alkyl, -CN
-Hal, -O-(C1-C10)-alkyl, -NR6R7 wherein R6, R7 have the meaning defined above -OH, with the exception of -CH(CH3)2, or -C(CH3)=CH2, and their salts, solvates or salts of solvates.
3. Compounds of general formula I according to claim 1, wherein R1, R2 and R3 are independently of one another hydrogen, fluorine, chlorine, bromine, a cyano group, a methoxy group, a ethoxy group, a hydroxy group R4 is hydrogen, C1-C3-alkyl, halogen, R5 is hydroxyl group, chlorine, -S-CH3, -S-CH2-CH3, -S-CH2-CH2-CH3, -O-CH3 or -O-CH2-CH3, -O-CH2-CH2-CH3, and their salts, solvates or salts of solvates.
4. Compounds according to at least one of claims 1-3 in enantiomerically pure form and their salts, solvates or salts of solvates.
5. Compounds according to claim 1 selected from the list consisting of 5-{[1-(2-Fluoro-4-methoxyphenyl)-3,3, 3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1H-quinolin-2-one 5-{[2-([Ethylsulfanyl]methyl)-1-(2-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-1H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-([ethylsulfanyl]methyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(ethoxymethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)-propyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-2-(chloromethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[3,3,3-trifluoro-2-hydroxy-2-([methoxymethyl)-1-phenylpropyl]amino}-1H-quinolin-1-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(diaminomethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(4-Chloro-3-fluoro-2-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(ethoxymethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[1-(2-Chloro-3-fluoro-4-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one and their salts, solvates or salts of solvates.
6. Enantiomerically pure Compounds according to claim 1 selected from the list consisting of 5-{(1S, 2R)[1-(2-Fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1H-quinolin-2-one 5-{(1S, 2R)[2-([Ethylsulfanyl]methyl)-1-(2-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-1H-quinolin-2-one 5-{(1S, 2R)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-([methylsulfanyl]methyl)propyl]amino}-1H-quinolin-2-one 5-{(1S, 2R)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2- ([ethylsulfanyl]methyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{(1S, 2S)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one 5-{(1S, 2S)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(ethoxymethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{(1S, 2S)[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one 5-{(1S, 2S)[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one 5-{(1S, 2R)[1-(5-Chloro-3-fluoro-2-methoxyphenyl)-2-(chloromethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{(1S, 2S)[3,3,3-trifluoro-2-hydroxy-2-([methoxymethyl)-1-phenylpropyl]amino}-1H-quinolin-1-one 5-{(1S, 2R)[[1-(2-Chloro-3-fluoro-4-methoxyphenyl)-2-(diaminomethyl)-3,3,3-trifluoro-2-hydroxypropyl]amino}-7-fluoro-1H-quinolin-2-one 5-{[(1S, 2S)[1-(2-Chloro-3-fluoro-4-hydroxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(hydroxymethyl)propyl]amino}-7-fluoro-1H-quinolin-2-one and their salts, solvates or salts of solvates.
7. Use of the compounds according to formula I of at least one of claims 1-6 for the manufacture of pharmaceutical agents.
8. Use of the compounds according to formula I of at least one of claims 1-6 for the manufacture of pharmaceutical agents for treating inflammatory diseases.
9. A pharmaceutical composition comprising a compound or formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1-6, and a pharmaceutically acceptable adjuvant, diluent or carrier.
10. Process for the manufacture of the compounds of general formula I
according to claim 1, wherein the following steps are performed:
step a):

(IV) (VI) step c):

wherein all residues have the definitions as given in claim 1 and R is C1-C4-alkyl and Met means alkalimetals, alkaline earth metals, aluminium, copper, silicon or tin.
11. Process step a) according to claim 10 for the manufacture of intermediates of general formula IV, characterized in that benzaldehydes of general formula II
are reacted with substituted quinolone amines of formula III to imines of general formula IV in the presence of Lewis acids and/or under acidic conditions, wherein R1, R2, R3and R4 have the meanings that are defined in claim 1 and R is C1-C4-alkyl.
12. Process step b) according to claim 10 for the manufacture of intermediates of general formula VI, characterized in that metallated trifluoroepoxipropane V, optionally being in its enantiomerically pure form, is reacted with imines of formula IV at low temperatures to yield epoxides of general formula VI

wherein R1, R2, R3and R4 have the meanings that are defined in claim 1 and optionally subsequently a separation of diastereoisomers is performed.
13. Process step c) according to claim 10 for the manufacture of compounds of general formula I, characterized in that epoxides of general formula VI
optionally in its enantiomerically pure form are are reacted with compounds of general formula R5-Met whereby Met means alkalimetals, alkaline earth metals, aluminium, copper, silicon or tin and R5 has the definitions as defined in claim 1, in the presence of Lewis acids, or are opened directly by cyanides, amines, alcohols, thioalcoholes, halogenides and/or water in the presence of bases or strong protic acids.
to yield compounds of general formula I

wherein R1, R2, R3, R4 and R5 have the meanings that are defined in claim 1 and optionally subsequently a separation of diastereoisomers is performed.
14. Compounds of general formula VI according to claim 12, in form of a racemic mixture or as enantiomerically pure isomer.
15.. Process for the manufacture of the compounds of general formula I
according to claim 1, wherein the following steps are performed:
step a):

step b):

step c):

wherein all residues have the meaning as defined in claim 1, Met means alkalimetals, alkaline earth metals, aluminium, copper, silicon or tin and R is C1-C4-alkyl.
16. Process step a) according to claim 15 for the manufacture of intermediates of general formula VIII, characterized in that N-methoxy-N-methyl amides of general formula VII are reacted with the lithiated epoxide optionally in its enantiomerically pure form (V) to yield compounds of type VIII wherein R1, R2and R3 have the meanings that are defined in claim 1 and optionally subsequently a separation of enantiomers is performed.
17. Process step b) according to claim 15 for the manufacture of intermediates of general formula IX, in a process for the manufacture of compounds of general formula I, characterized in that epoxides of general formula VIII
optionally in its enantiomerically pure form are reacted with compounds of general formula R5-Met wherein R1, R2, R3 and R5 have the meanings that are defined in claim 1 and Met has the meaning as defined in claim 13 and optionally subsequently a separation of enantiomers is performed.
18. Process step c) according to claim 15 for the manufacture of compounds of general formula I, characterized in that ketones of type (IX) optionally in its enantiomerically pure form can be condensed with substituted amino quinolones of type (III) to imines and subsequently or simultaneously reduced to yield compounds formula I

wherein R1, R2, R3, R4 and R5 have the meanings that are indicated in claim 1 and R as defined in claim 11 and optionally subsequently a separation of diastereoisomers may be performed.
19. Compounds of the general formula VIII according to claim 16 in form of a racemic mixture or as enantiomerically pure isomer.
20. Compounds of the general formula IX according to claim 17 form of a racemic mixture or as enantiomerically pure isomer.
21. A combination of a compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more agents selected from the list comprising:

.cndot. a PDE4 inhibitor including an inhibitor of the isoform PDE4D;
.cndot. a selective .beta..sub2. adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol or indacaterol;
.cndot. a muscarinic receptor antagonist (for example a M1, M2 or M3 antagonist, such as a selective M3 antagonist) such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine;
.cndot. a modulator of chemokine receptor function (such as a CCR1 receptor antagonist); or, .cndot. an inhibitor of p38 kinase function.
CA2705410A 2007-11-22 2008-11-08 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents Expired - Fee Related CA2705410C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07076019A EP2062880A1 (en) 2007-11-22 2007-11-22 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
EP07076019.4 2007-11-22
PCT/EP2008/009440 WO2009065503A1 (en) 2007-11-22 2008-11-08 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents

Publications (2)

Publication Number Publication Date
CA2705410A1 true CA2705410A1 (en) 2009-05-28
CA2705410C CA2705410C (en) 2016-04-12

Family

ID=39575536

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2705410A Expired - Fee Related CA2705410C (en) 2007-11-22 2008-11-08 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents

Country Status (40)

Country Link
US (3) US8394958B2 (en)
EP (2) EP2062880A1 (en)
JP (1) JP5559058B2 (en)
KR (1) KR101580700B1 (en)
CN (2) CN103396300A (en)
AR (1) AR069400A1 (en)
AU (1) AU2008328307C1 (en)
BR (1) BRPI0819833B1 (en)
CA (1) CA2705410C (en)
CL (1) CL2008003472A1 (en)
CO (1) CO6280419A2 (en)
CR (1) CR11452A (en)
CU (1) CU23889B1 (en)
CY (1) CY1118173T1 (en)
DK (1) DK2234979T3 (en)
DO (1) DOP2010000152A (en)
EA (1) EA017459B1 (en)
EC (1) ECSP10010192A (en)
ES (1) ES2588170T3 (en)
HK (1) HK1144817A1 (en)
HN (1) HN2010001060A (en)
HR (1) HRP20161015T1 (en)
HU (1) HUE028865T2 (en)
IL (1) IL205117A (en)
LT (1) LT2234979T (en)
MA (1) MA31834B1 (en)
MX (1) MX2010005528A (en)
MY (1) MY151017A (en)
NZ (1) NZ585495A (en)
PA (1) PA8804601A1 (en)
PE (1) PE20091066A1 (en)
PL (1) PL2234979T3 (en)
PT (1) PT2234979T (en)
RS (1) RS55012B1 (en)
SI (1) SI2234979T1 (en)
TN (1) TN2010000219A1 (en)
TW (1) TWI520736B (en)
UA (1) UA100251C2 (en)
UY (1) UY31479A1 (en)
WO (1) WO2009065503A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878717A1 (en) 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US20100016338A1 (en) * 2008-07-21 2010-01-21 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents
JP6061373B2 (en) * 2012-07-24 2017-01-18 国立研究開発法人産業技術総合研究所 2-Hydroxybenzaldehyde compound, collagen extracellular secretion inhibitor and pharmaceutical composition containing the same
WO2017025371A1 (en) * 2015-08-07 2017-02-16 Bayer Pharma Aktiengesellschaft Process for the preparation of 5-amino-quinolin-2(1h)-ones and their tautomer forms 5-amino-quinolin-2-ols
WO2017081044A1 (en) 2015-11-13 2017-05-18 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
WO2018046684A1 (en) 2016-09-08 2018-03-15 Bayer Pharma Aktiengesellschaft Process for the preparation of substituted 5-{[2-(alkoxymethyl)-3,3,3-trifluoro-2-hydroxy-1-phenylpropyl]amino}quinolin-2(1h)-ones
WO2018046681A1 (en) 2016-09-08 2018-03-15 Bayer Pharma Aktiengesellschaft Forms of 5-{[(1s,2s)-1-(2-chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1h-quinolin-2-one
WO2018046678A1 (en) 2016-09-08 2018-03-15 Bayer Aktiengesellschaft Formulations containing glucocorticoid receptor agonists
WO2018046685A1 (en) 2016-09-08 2018-03-15 Bayer Aktiengesellschaft Quinoline derivatives for treatment of inflammatory skin diseases
AU2020211303A1 (en) * 2019-01-22 2021-07-15 Akribes Biomedical Gmbh Selective Glucocorticoid Receptor Modifiers for treating impaired skin wound healing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1045180A (en) * 1963-09-20 1966-10-12 Parke Davis & Co Quinazoline derivatives
US4197209A (en) * 1977-03-10 1980-04-08 Ciba-Geigy Corporation Lubricant compositions containing sulfur-containing esters of phosphoric acid
JPH06172321A (en) 1992-10-08 1994-06-21 Agro Kanesho Co Ltd Substituted aminopyrimidine derivative, its production and pest exterminating agent comprising the same as active ingredient
UA57002C2 (en) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. (methylsulfonyl)phenyl-2-(5n)-furanon derivative, a pharmaceutical composition and a method for treatment
AU5682299A (en) 1998-08-21 2000-03-14 Scripps Research Institute, The Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles
DE10038639A1 (en) 2000-07-28 2002-02-21 Schering Ag New and known N-aryl 2-hydroxy-omega-arylalkanamide derivatives, useful e.g. for treating inflammatory diseases such as rheumatism
ES2270955T3 (en) 2000-12-22 2007-04-16 Smithkline Beecham Plc MESILATE SALT OF 5- (4- (2- (N-METHYL-N- (2-PIRIDIL) AMINO) ETOXI) BENCIL) THYZOLIDINE-2,4-DIONA.
EP1490317A1 (en) * 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20050090559A1 (en) * 2003-07-01 2005-04-28 Markus Berger Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
EA200600148A1 (en) 2003-07-01 2006-08-25 Шеринг Акциенгезельшафт HETEROCYCLICALLY SUBSTITUTED DERIVATIVES OF PENTANOL, METHOD OF THEIR RECOVERY AND THEIR APPLICATION AS INFLAMMATION INHIBITORS
US20050009109A1 (en) * 2003-07-08 2005-01-13 Stanford University Fluorophore compounds and their use in biological systems
DE10347385A1 (en) 2003-10-08 2005-05-12 Schering Ag Rearranged pentanols, a process for their preparation and their use as anti-inflammatory agents
EP1878717A1 (en) * 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
US20100016338A1 (en) * 2008-07-21 2010-01-21 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents

Also Published As

Publication number Publication date
PA8804601A1 (en) 2009-06-23
CO6280419A2 (en) 2011-05-20
DOP2010000152A (en) 2010-08-15
IL205117A0 (en) 2010-11-30
NZ585495A (en) 2011-05-27
DK2234979T3 (en) 2016-09-05
CU23889B1 (en) 2013-04-19
EA201000814A1 (en) 2010-12-30
AR069400A1 (en) 2010-01-20
TW200927112A (en) 2009-07-01
BRPI0819833A2 (en) 2015-05-26
AU2008328307C1 (en) 2013-10-24
EP2234979B1 (en) 2016-05-25
HN2010001060A (en) 2012-11-12
UA100251C2 (en) 2012-12-10
UY31479A1 (en) 2009-07-17
HRP20161015T1 (en) 2016-11-18
SI2234979T1 (en) 2016-12-30
EP2234979A1 (en) 2010-10-06
ECSP10010192A (en) 2010-07-30
MA31834B1 (en) 2010-11-01
EA017459B1 (en) 2012-12-28
JP2011504472A (en) 2011-02-10
WO2009065503A1 (en) 2009-05-28
RS55012B1 (en) 2016-11-30
US20130005766A1 (en) 2013-01-03
US20090137564A1 (en) 2009-05-28
TWI520736B (en) 2016-02-11
CY1118173T1 (en) 2017-06-28
ES2588170T3 (en) 2016-10-31
CA2705410C (en) 2016-04-12
JP5559058B2 (en) 2014-07-23
PL2234979T3 (en) 2016-11-30
MX2010005528A (en) 2010-06-02
HUE028865T2 (en) 2017-01-30
CL2008003472A1 (en) 2009-11-20
AU2008328307A1 (en) 2009-05-28
MY151017A (en) 2014-03-31
HK1144817A1 (en) 2011-03-11
CN103396300A (en) 2013-11-20
KR101580700B1 (en) 2015-12-28
PE20091066A1 (en) 2009-08-27
IL205117A (en) 2015-05-31
KR20100092936A (en) 2010-08-23
TN2010000219A1 (en) 2011-11-11
USRE47047E1 (en) 2018-09-18
CU20100099A7 (en) 2011-10-14
AU2008328307B2 (en) 2013-03-28
EP2062880A1 (en) 2009-05-27
PT2234979T (en) 2016-08-29
CN101868448B (en) 2013-06-12
BRPI0819833B1 (en) 2018-11-27
US8394958B2 (en) 2013-03-12
US8680117B2 (en) 2014-03-25
CN101868448A (en) 2010-10-20
CR11452A (en) 2010-07-15
LT2234979T (en) 2016-11-10

Similar Documents

Publication Publication Date Title
CA2705410C (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
CA2586689C (en) 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
US7417056B2 (en) 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
CA2657006C (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents
CA2586973A1 (en) Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
AU2004279583A1 (en) Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics
US20070015761A1 (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20060167025A1 (en) Tricyclic amino alcohols, processes for synthesis of same and use of same as anti-inflammatory drugs
US20100016338A1 (en) 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents
WO2010009814A1 (en) 5-[ (3,3,3-trifluoro-2-hydroxy-1-arylpropyl) amino]-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents
AU2013203708A1 (en) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents
WO2010049073A1 (en) 1,1,1-trifluoro-3-amino-3-heteroaryl-2-propanoles, a process for their production and their use as anti-inflammatory agents
DE102004017662B3 (en) New 1-amino-tetrahydronaphthalene derivatives, useful for treatment of e.g. inflammation, bind with high selectivity to glucocorticoid receptors
US20070129358A1 (en) Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents
EP2072509A1 (en) 1-Aryl-1H-quinoline-2-ones: process for their production and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131104

MKLA Lapsed

Effective date: 20201109